Enzyme News and Research

RSS

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

A recent study posted to the medRxiv* preprint server reported the phase one pharmacokinetic and safety data of nirmatrelvir/ritonavir to facilitate its rapid progression to the last stages of clinical trials in coronavirus disease 2019 (COVID-19) patients with mild to moderate disease.

14 Feb 2022

UCI biologists discover how a protective mutation may reduce Alzheimer's risk

While the word "mutation" may conjure up alarming notions, a mutation in brain immune cells serves a positive role in protecting people against Alzheimer's disease.

14 Feb 2022

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

Researchers suggest that extracellular vimentin may act as a coreceptor to allow for SARS-CoV-2 entry into cells.

14 Feb 2022

Discovery may lead to new treatment approach for people with alcohol-associated liver disease

Investigators at Cedars-Sinai have uncovered a new pathway that helps explain how consuming too much alcohol causes damage to the liver, specifically mitochondrial dysfunction in alcohol-associated liver disease.

14 Feb 2022

Research lays the foundation for developing obesity drugs based on enhancing β-AR signaling

Following up on a 2018 study that identified an epigenetic modifier known as histone deacetylase 11 (HDAC11) as a potential therapeutic target for treating obesity and diabetes, researchers from the University of Colorado School of Medicine have published new research that finds HDAC11 regulates G protein-coupled receptors (GPCRs) called beta-adrenergic receptors (β-ARs).

14 Feb 2022

Variations in the neutralization of SARS-CoV-2 variants in vaccinated mice and primates

In a new study, researchers demonstrated the variations in the neutralizing antibody responses induced by SARS-CoV-2 vaccines in humans, non-human primates, and mice against the SARS-CoV-2 variants of concern.

14 Feb 2022

Study describes a β-CoV spike protein target for protective antibodies that may facilitate pan-β-CoV vaccine development

In a recent study published in Science Translational Medicine, researchers characterized a human antibody targeting betacoronaviruses (β-CoVs).

14 Feb 2022

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

A new study was based on the hypothesis that competitively inhibiting cellular furin and selectively targeting SARS-CoV-2 in the infected viral-producing cells is critical for therapeutic specificity.

14 Feb 2022

Researchers identify autoantibody targets in COVID-19 patients

In a new study, researchers have been investigating auto-immune responses to natural human antigens in COVID-19 patients.

14 Feb 2022

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted mRNA-1273.529 vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 Omicron infection in mice.

14 Feb 2022

Nitazoxanide shows promise for COVID-19 treatment in animal model

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that Nitazoxanide (NTZ), an oral drug, broadly inhibits replication of several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in preclinical models of infection.

13 Feb 2022

Testes found to be a viral reservoir for SARS-CoV-2 replication

In a recent study posted to the medRxiv* pre-print server, researchers used a suite of methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the testis of patients who died from coronavirus disease 2019 (COVID-19) to gain insights into SARS-CoV-2 tropism inside testis and its impact on male fertility.

13 Feb 2022

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

A recent paper by researchers from Australia, currently available on the medRxiv* preprint server, shows how Immunoglobulin A (IgA) antibodies in individuals who were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to the neutralization of the virus and its variants, even though this response is heterogeneous and less potent when compared to IgG antibodies.

13 Feb 2022

Enzyme News and Research

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

UCI biologists discover how a protective mutation may reduce Alzheimer's risk

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

Discovery may lead to new treatment approach for people with alcohol-associated liver disease

Research lays the foundation for developing obesity drugs based on enhancing β-AR signaling

Variations in the neutralization of SARS-CoV-2 variants in vaccinated mice and primates

Study describes a β-CoV spike protein target for protective antibodies that may facilitate pan-β-CoV vaccine development

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

Researchers identify autoantibody targets in COVID-19 patients

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

Nitazoxanide shows promise for COVID-19 treatment in animal model

Testes found to be a viral reservoir for SARS-CoV-2 replication

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

Study provides evidence for spike protein-independent attenuation of SARS-CoV-2 Omicron variant

Novel molecule shows ability to inhibit the replication of all coronaviruses

Scientists introduce a genetic mutation to provide protection against Alzheimer's disease

Spillover of SARS-CoV-2 Omicron variant infection in white-tailed deer in New York

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

The effect of Omicron mutations at the fundamental atomic scale level

Understanding the DNA Damage Response in Innate Immunity eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo